The Cairn GEBT is intended for measurements of the rate of solid-phase gastric emptying and as an aid in the diagnosis of delayed gastric emptying (gastroparesis) in symptomatic adults. Approved by the FDA in 2015, the GEBT has been validated against the method of gastric scintigraphy.
The Cairn GEBT is a proven method for the rapid and accurate diagnosis of gastroparesis. The test is non-radioactive and non-invasive and can be administered conveniently at a physician’s office, a laboratory collection center or in a tertiary care setting.
Patient breath samples are returned to Cairn’s CLIA-certified clinical laboratory for analysis by gas isotope ratio mass spectrometry (GIRMS). The GIRMS platform is a validated, FDA-approved analytical system for conducting GEBT breath analyses. GEBT test results are presented to the ordering clinician in a simple, easy to interpret report.
Cairn Diagnostics presentations at DDW 2016 include:
Cairn Diagnostics GEBT for Gastroparesis Product Theater
- Monday, May 23 from 1:15 to 2:00pm
- DDW Product Theater, Exhibit Hall A
DDW 2016 attendees are also encouraged to visit booth #761 to learn more about Cairn Diagnostics and the GEBT for gastroparesis.
About Cairn Diagnostics
For many diseases and conditions, the pathway to a definitive diagnosis can be complex, slow and frustrating. At Cairn Diagnostics, our mission is to develop tests that eliminate complexity and create a safer, faster and clearer path to diagnosis. Use of our proprietary and validated analytical methods allows us to create diagnostic tests that are user and patient-friendly and easy to administer, yet powerful in their ability to deliver a definitive diagnosis. Cairn Diagnostics is based in Brentwood, Tennessee. For more information, please visit www.cairndiagnostics.com.